Adalvo is pleased to announce our successful DCP closure for Fulvestrant pre-filled injection.
Our product is a fully EU compliant generic version of Faslodex, which is a widely used drug, indicated in estrogen receptor positive, locally advanced, or metastatic breast cancer, in postmenopausal women.
This product is very complimentary to the broad oncology portfolio of Adalvo and creates additional synergies for our existing partners in the market. The product sold at around $712 million in 2021, according to IQVIA.
While Fulvestrant generics are available in Europe, Adalvo and its partners believe that this positive progress, combined with competitive manufacturing of the product, and Adalvo's wide network of strategic partners, are the basis for a solid product launch.
Disclaimer: Fulvestrant pre-filled injection, which is subject to patent protection is currently not offered or made available in countries where patents are in force.